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Abstract In contrast to immortal cell lines, primary cells are
hardly susceptible to intracellular delivery methods such as
transfection. In this study, we evaluated the direct delivery of
several cell-permeable peptides under noninvasive condi-
tions into living primary adult rat cardiomyocytes. We
specifically monitored the functional effects of a cell-
permeable peptide containing the 15 amino acid N-terminal
peptide from human ventricular light chain-1 (VLC-1) on
contraction and intracellular Ca
2+ signals after electrical
stimulation in primary adult cardiomyocytes. The trans-
ducible VLC-1 variant was taken up by cardiomyocytes
within 5 min with more than 95% efficiency and localized
to sarcomeric structures. Analysis of the functional effects
of the cell-permeable VLC-1 revealed an enhancement of
the intrinsic contractility of cardiomyocytes without affect-
ing the intracellular Ca
2+. Therefore, peptide transduction
mediated by cell-penetrating peptides represents not only a
unique strategy to enhance heart muscle function with no
secondary effect on intracellular Ca
2+ but also an invaluable
tool for the modulation and manipulation of protein
interactions in general and in primary cells.
Keywords Ventricularlightchain-1(VLC-1).
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Introduction
Therapeutical delivery of protein or peptides into living
primary cells is hampered by the lack of a suitable and
efficient method for the introduction of macromolecules.
Most commonly used transfections methods work in immor-
talized cells but mostly fail in primary cells or require
specialized and time-consuming protocols, i.e., production
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cells often does not provide sufficient time for expression of
gene products and subsequent analysis of their effects.
Physical methods such as microinjection and bead loading
arehighlyinvasiveproceduresandarenottoleratedbyseveral
cell types. It has been known for quite some time that basic
proteins like histones or poly-ornithine as well as stretches of
basic amino acids within proteins aid the uptake of proteins
into mammalian cells [14, 17, 20, 30]. In the 1990s,
transducible peptides like penetratin-1 from the homeodo-
main of Antennapedia [11] and amino acids 48–57 from the
transactivator of transcription of human immunodeficiency
virus (HIV)-1 [14] were identified and exploited to introduce
drugs or biological macromolecules into mammalian cells.
Together with other native and synthetic transducing
peptides, they are referred to as cell-penetrating peptides
(CPPs) [12]. However, it became evident that the invasive
methods used to analyze the transduction mediated by CPPs
or effects of interconnected cargoes had led to overestimated
transduction results and overrated effects of cargoes fused to
CPPs [27]. Nevertheless, CPPs mediate the introduction of
fused cargoes into living cells, with cargo-dependent
mechanistical differences. One uptake mechanism can be
described as a slow adsorptive endocytosis and is preferen-
tially used by globular proteins, whereas small compounds
like peptides linked to CPPs favor a rapid membrane
potential-dependent uptake with overall intracellular avail-
ability of the transduced species [33]. CPP-mediated peptide
transduction has recently been used to deliver cardioprotec-
tive peptides derived from protein kinase C [4, 7–9, 24], the
antiapoptotic BH4 peptide derived from the apoptosis
regulator protein Bcl-xL [26, 28] and a Nox2-derived
peptide [34] into isolated cardiomyocytes or whole hearts.
We have tested the feasibility of this approach to study
muscle function in living adult primary cardiomyocytes.
Therefore, we targeted the interaction between actin and the
essential myosin light chain (MLC-1) of cardiac type II
myosin by a peptide competition approach. Transgenic
overexpression of the N terminus of the human ventricular
MLC-1 (residues 1–15; hereafter termed VLC-1), which
binds to actin and targets actin/MLC-1 interaction, signif-
icantly increased the magnitude and kinetics of the contrac-
tion of isolated perfused hearts [21]. We fused the same
human VLC-1 peptide to the TAT CPP (VLC-1-TAT) and
investigated its uptake, intracellular distribution, and function-
al consequences in primary living adult rat cardiomyocytes.
Materials and methods
Isolation of adult rat cardiomyocytes Primary cultures of
cardiomyocytes from male WKY rats aged 3 months were
performed as described previously [1].
Peptides The peptides consisted of either L-amino acids
(capital letters) or of D-amino acids (lower case letters). In
case of D-amino acid peptides, functional motifs were
synthesized as retro-all D-variants (underlined) to maintain
their functionality. Peptides were either labeled with the
fluorophore 5,6-carboxy-tetramethylrhodamine (TAMRA)
or fluorescein isothiocyanate (FITC). TAT (TAMRA- or
FITC-rrrqrrkkrg), PTD4 [23, 33] (TAMRA-araqraaaray),
and TAT-p21 (TAMRA-rrrqrrkkrgaaAGRKRRQTSMT
DFYHSKRRLIFSa-amide) [33] were labeled directly at
their N termini with the indicated fluorophores (Peptide
Speciality Laboratories, Heidelberg). In the case of VLC-1
(MAPKKPEPKKSSAKA-C-TAMRA-ME-amide) and
VLC-1-TAT (MAPKKPEPKDDAKAPAGRKKRRQRRR-
C-TAMRA-ME-amide; Biosyntan, Berlin) the TAMRA
fluorophore was coupled via an additional cysteine at the
C terminus leaving the N terminus free for the interaction
with actin.
Uptake of transducible peptides and controls To analyze
the transduction ability of different compounds into living
adult ventricular cardiomyocytes, the primary cells were
plated into a laminin-coated μ-slide eight-well ibiTreat
(ibidi, Martinsried) or four-well labtek (Nunc, Wiesbaden)
microscopy observation chamber. The respective peptides
and controls were added directly to Hank’s balanced salts
solution buffered with 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid at pH 7.4 (HBSS) or
medium and gently shaken to yield a final concentration
of 10 μM in case of the peptides and 5,6-TAMRA-
fluorophore. Trypan blue (Sigma-Aldrich) was added to a
final concentration of 0.5% (v/v) to the HBSS buffer. For
the experiments summarized in Fig. 1 confocal images
w e r ea c q u i r e d1ha f t e ra d d ition of the respective
compounds to living cardiomyocytes. To study the
intracellular localization of transducible peptides in
Fig. 3, after 15 min of peptide incubation, the medium
was removed, and the cells were washed twice with the
HBSS buffer. For subsequent confocal image collection,
the cells were kept in medium or buffer. To study the
effect of the peptide on muscle contraction and intracel-
lular Ca
2+ (Fig. 4), cardiomyocytes were electrically
stimulated (see below) to permit the access of the peptides
to all actin molecules with potential binding sites. During
confocal image collection, the electric stimulation was
temporarily switched off.
Microscopy, image acquisition, and analysis Confocal
images were acquired with a Zeiss laser scanning micro-
scope LSM510 Meta mounted on an Axiovert 200M
inverted microscope using a 63× phase-contrast oil immer-
sion plan-apochromat objective NA1.4 or a 100× phase-
contrast oil immersion plan-neofluar objective NA1.3. For
1406 J Mol Med (2007) 85:1405–1412all settings, the main beam splitter was HFT UV/488/543/
633, and the specific parameters for the single fluorophores
were: FITC, excited at 488 nm light, detected with a 500–
530-nm bandpass filter; TAMRA or rhodamine excited at
543 nm, detected with 565–615 bandpass filter; and trypan
blue, excited with 633 nm, detected with 650 longpass
filter. Phase-contrast images were recorded with excitation
at 488 nm and detection in the transmission channel. Laser
power for observation was typically 1–5% (488 nm,
25 mW) and 50–60% (543 nm, 1 mW) unless otherwise
indicated. Settings were adjusted in a way that image pixels
were not over- or underexposed with the range indicator
function in the Zeiss LSM image acquisition and examiner
software version 3.2.
Measurement of cardiomyocyte shortening and Ca
2+
transients Attached cardiomyocytes were washed with
HBSS. Cells were loaded with Fura-2-AM for 30 min at
room temperature in the dark. The dye solution was removed,
and cells were left on HBSS for another 15 min. Only
cardiomyocytes of optically intact rod-shaped morphology
with clear cross-striation were analyzed. Cardiomyocytes
were electrically stimulated until a stable steady-state
contraction and Fura-2 signal could be monitored.
Cell shortening and Fura-2 signals were simultaneously
measured at 30°C on an Ionoptix Contractility and
Fluorescence System (Ionoptix). Cardiomyocytes were
electrically stimulated with bipolar pulses of 5 ms duration
at 1 Hz. Cell shortening, expressed as percentage of resting
cell length, was measured using the video-edge technique at
a sampling rate of 240 per second. Ca
2+ transients were
monitored as ratio of fluorescence emission at 510 nm was
obtained by alternate excitation at 340 and 380 nm (340/
Fig. 1 Peptide uptake and in-
tracellular distribution in living
adult cardiomyocytes. To study
the uptake capacity of different
compounds into primary rat
cardiomyocytes, different fluo-
rescent compounds were direct-
ly added for 1 h to the medium
or buffer of freshly isolated
cardiomyocytes. After the incu-
bation period, confocal images
of the cells were taken without
exchange of the medium and
after removal of the fluorescent
solution and exchange against
the fresh medium. Internaliza-
tion into healthy adult cardio-
myocytes occurred after
application of 10 μM of the
transducible peptides FITC-TAT
shown at low (a) and high
magnification (b) and TAMRA-
TAT-p21 shown at low (c) and
high magnification (d) but not
with application of 10 μMo fa
basic control peptide PTD4 (e).
Moreover, 0.5% of the vital dye
trypan blue (f)o r1 0μM of the
TAMRA-fluorophore (g) itself
were not able to enter healthy
cardiomyocytes (rod-shaped
cells in culture). Scale bar,
10 μm. Stars indicate the nuclei
and arrowheads the nucleoli (N)
in the higher magnification
images. PC Phase contrast, NP
nucleoplasm
J Mol Med (2007) 85:1405–1412 1407380 ratio). Data files from 15 consecutive beats recorded at
intervals were averaged for analysis. Subsequently, the
cardiomyocytes were incubated with the peptides for
15 min without electrical stimulation. The peptide was then
removed by replacing the peptide-containing HBSS buffer
with normal HBSS buffer without the peptide. The
cardiomyocytes were subsequently electrically stimulated,
and both the shortening and Fura-2 signals were simulta-
neously recorded. The effect of the peptide on shortening
amplitude and the Fura-2 signal was expressed in percent
change compared to the steady-state signals obtained in the
preincubation period.
Results and discussion
We recently demonstrated by live-cell confocal microscopy
that the TAT CPP was able to shuttle fused peptides into
primary blood cells and subsequently modulated their
functional properties [10]. In this study, we tested whether
TAT CPP could penetrate and if a peptide derived from the
N terminus of VLC-1 fused to TAT is able to modulate the
contractile function of primary adult cardiomyocytes.
Different basic peptides were incubated with freshly
prepared cultures of cardiomyocytes, and peptide internal-
ization was analyzed live by laser-scanning confocal
microscopy. The fluorescently labeled minimal transduction
domain TAT CPP of the transactivator of transcription from
HIV-1 was readily taken up into cardiomyocytes and
displayed a strong affinity to the nuclear compartment
(Fig. 1a). It could also be visualized in a punctate pattern
throughout the entire cardiomyocyte (Fig. 1a). To determine
whether the TAT CPP is able to shuttle an attached peptide
into cardiomyocytes, we used the TAMRA-labeled TAT-
p21
WAF/CIP (TAT-p21) fusion peptide [33], which in
addition to the transducing moiety contains 26 amino acids
derived from the C terminus of human p21
WAF/CIP protein.
The uptake of this cargo peptide (assessed by appearance in
nucleoli) occurred on a timescale of 5 to 10 min after
peptide application. Its pattern of localization inside the
cardiomyocytes was similar than that seen for TAT alone
(Fig. 1c). Basic amino acid residues are a prerequisite for
the transduction ability of CPPs [13, 25, 35], and peptides
containing a minimum of six basic amino acids have been
shown to traverse biological membranes [5, 18]. As a
nontransducing control peptide, we chose the TAMRA-
labeled peptide PTD4, which contains three arginines in
total [23, 33]. More than 1 h after application of this peptide
to the cardiomyocyte culture, none of the healthy intact
cardiomyocytes took up the fluorescent peptide (Fig. 1e).
Similar results were obtained for the vital dye trypan blue
(Fig. 1f) and the TAMRA fluorophore (Fig. 1g). Approx-
imately 5% of cardiomyocytes in the cultures were dead or
Fig. 2 Molecular hypothesis for the enhancement of cardiomyocyte
contractility by the cell-permeable VLC-1 peptide. a Primary
sequence of VLC-1-TAT peptide color-coded orange for the VLC-1-
and yellow for the TAT-moiety. b Schematic sliding filament model
displaying actin in violet and the MHC in red. The higher
magnification shows the catalytic domain (CD) and the neck domain
(ND) of one molecule of the MHC. MLC proteins are colored green
with the N-terminal SE inside the essential MLC-1 protein highlighted
in red. Upon intramolecular conformational changes in the CD of
MHC, the ND swings out, exposing the SE of MLC-1 to an actin
molecule in direction to the Z-line. Treatment of cardiomyocytes with
the transducible TAT peptide (yellow ball) fused to the SE-peptide
(orange) blocks potential binding sites of the native MLC-1 N
terminus. After the MHC rearrangement, the MLC-1 protein can no
longer interact with actin and downregulate the myosin motor activity.
The scheme is based on the pre- and postpower stroke model [19]
developed with respect to crystallographic data on the Dicytostelium
myosin motor domain [15, 32]
1408 J Mol Med (2007) 85:1405–1412harmed (visible in the phase-contrast images as not rod
shaped and with no striations). These cells were flooded
with both the CPPs as well as any other control dyes
(Fig. 1c,e–g). The cell-permeable TAT-derived peptides
displayed a similar enrichment in the nuclear compartment
with strong accumulation inside nucleoli (arrowheads) as
can be seen in the higher magnification images (Fig. 1b,d).
This intranuclear distribution is basically determined by the
TAT moiety, which includes a nuclear localization sequence
[22, 29, 33].
Having shown that CPP TAT was able to shuttle fused
peptides into living cardiomyocytes, we designed a trans-
ducible peptide comprising the actin-binding element of the
ventricular isoform of human MLC-1 (VLC-1), i.e., the N-
terminal residues 1–15 (VLC-1 peptide) connected to TAT,
termed VLC-1-TAT (Fig. 2). The hearts of transgenic
animals harboring minigenes encoding for the VLC-1
peptide revealed enhanced myosin motor activity and
positive inotropic effects [21]. A possible molecular
mechanism for the increase in myosin motor activity and
contractility is illustrated in the scheme in Fig. 2. MLC-1
isoforms of vertebrate striated muscle play a regulatory role
in myosin motor function: The N-terminal part of MLC-1
contains a sticky element (SE), which consists of several
positively charged amino acids that bind to the C terminus
of actin [3, 6, 16, 31]. The 46 N-terminal amino acids of
MLC-1 have previously been modeled on the basis of
contemporary crystallographic data [2]. Interactions be-
tween the sticky MLC-1 element and actin serve as a
negative modulator and decrease the activity of the myosin
motor domain. Intracellular delivery of a synthetic sticky
MLC-1 element by TAT-mediated transduction therefore
would antagonize MLC-1/actin interaction. We predict this
would increase myosin motor activity and enhance the
shortening amplitude without change of the systolic free
Ca
2+ activation level of intact cardiomyocytes.
To first test whether the VLC-1 peptide itself might be
taken up by isolated cardiomyocytes because of its basic
charge, VLC-1 and VLC-1-TAT were applied for 15 min to
freshly isolated cardiomyocytes under resting conditions or,
Fig. 3 Transduction and intracellular localization of VLC-1-TAT in
isolated adult cardiomyocytes. a Scheme for the application of the
VLC-1-derived peptides and confocal imaging. Peptides were applied
at a concentration of 1 μM, incubated for 15 min to freshly isolated
cardiomyocytes. After removal of the peptide solution, the cells were
washed twice and kept in buffer or medium for direct live-cell
confocal imaging microscopy. Subsequently, the transduced cardio-
myocytes were electrically stimulated with 1 Hz for maximally 1 h. b
The negative control peptide TAMRA-labeled VLC-1 stained only
dead cardiomyocytes (low magnification, upper panel) but failed to
get internalized into healthy cardiomyocytes even when 100% laser
power was used to detect potentially weak signals (lower panel). c
Application of TAT-VLC-1 to living cardiomyocytes led to rapid
internalization of the peptide (upper panel). The lower panel shows
transduced VLC-1-TAT at higher magnification in an overlay of the
phase contrast and the TAMRA-fluorescence. The arrow indicates the
direction of the intensity profile of gray and red intensities in the line
scan for the localization analysis of VLC-1-TAT, which was present at
sarcomeric structures with enrichment at the actin-containing I-bands
(light bands in phase-contrast image)
J Mol Med (2007) 85:1405–1412 1409in another set of experiments, constant electric stimulation
(1 Hz, 20 V). After the fluorescent peptides were washed
away, the cells were analyzed live by confocal laser-
scanning microscopy (Fig. 3a). VLC-1 alone was not
internalized into healthy cardiomyocytes and stained only
compromised cells (upper panel, Fig. 3b). To ensure that
low concentrations of intracellular VLC-1 were not missed,
the laser intensity was increased to its maximum, and still
no fluorescent signals were measured (lower panel,
Fig. 3b). In contrast, VLC-1-TAT reached the intracellular
Fig. 4 Functional effects of cell
permeable VLC-1-TAT in living
adult cardiomyocytes. a Original
registration of cell length (top)
and cytosolic Ca
2+ signals
(Fura-2 signal, expressed as ra-
tio R between 340 and 380
excitation; bottom) of electrical-
ly paced adult rat cardiomyo-
cytes before (basal) and after
incubation with 1 μM VLC-
1-TAT or 1 μM TAT as control.
b Statistical evaluation of the
effects of different concentra-
tions of transducible peptides
(0.5, 1 μM) on fractional short-
ening (FS; given in percent of
basal contraction obtained be-
fore incubation with the pep-
tide), maximal rate of FS (+dFS/
dtmax), and maximal relaxation
rate (-dFS/dtmax; both given in
percent of basal values obtained
before peptide incubation) of
control peptide (TAT) and VLC-
1-TAT. c Statistical evaluation of
the effects of different concen-
trations of transducible peptides
(0.5, 1 μM) on peak Fura-2
fluorescence signal (expressed
as ratio R between 340 and 380
excitation, given in percent of
basal R340/380 obtained before
incubation with the peptide),
maximal rate of R340/380
(+dR340/380/dtmax), and maxi-
mal rate of fluorescence decline
(-dR340/380/dtmax; both given
in percent of basal values
obtained before peptide incuba-
tion) of control peptide (TAT)
and VLC-1-TAT. Values are
means±SEM, n=6–9 different
cardiomyocytes at each peptide
concentration used. Double as-
terisk, p<0.01; triple asterisk,
p<0.001 (t test for paired
values)
1410 J Mol Med (2007) 85:1405–1412compartments of more than 95% of adult cardiomyocytes
(Fig. 3c).
Unlike the localization of the TAT and TAT-p21 peptides
(Fig. 1), the VLC-1-TAT was not detected in the cell
nucleus. Detailed analysis of the intracellular distribution of
transduced VLC-1-TAT and correlation of the fluorescent
signals with the phase contrast images (merge image, lower
panel, Fig. 3c) demonstrated that the peptide associates
with sarcomeric structures. It showed strong enrichment at
the I-bands representing the nonoverlapping zones of the
thin actin filaments with the thick myosin filaments
(linescan, lower panel, Fig. 3c). After transduction, the
VLC-1-TAT peptide remained inside the sarcomeric compart-
ments of the cardiomyocytes for at least 1 h after transferring
the loaded cardiomyocytes into the peptide-free buffer
solution.
Using the same incubation protocol, we studied the
effects of the cell-permeable VLC-1 peptide on muscle
function by simultaneously monitoring the shortening
amplitude and the systolic and diastolic cytoplasmic Ca
2+
fluctuations (measured by Fura-2 fluorescence) of paced
adult rat cardiomyocytes (Fig. 4a). As shown in Figs. 4b
and c, 1 μM, but not 0.5 μM, of VLC-1-TAT significantly
increased the shortening amplitude of adult cardiomyocyte,
while the cytosolic Ca
2+ signal remained unchanged. The
same concentrations of control TAT peptide alone did not
change the contractile state or the Fura-2 signals if
compared to the basal state during the preincubation period.
Higher concentrations of both control and test peptides
induced deleterious effects on the cardiomyocyte contrac-
tion. It is interesting to note that not only the maximal
amplitude of shortening rose but also the maximal rate of
shortening and the maximal relaxation velocity increased
significantly. Because the Fura-2 signal remained un-
changed, the selective effect of the VLC-1-TAT peptide
on the contraction parameters suggests a selective and
direct effect on the function of the myosin cross-bridges.
The Ca
2+-sensitizing effect of the VLC-1-TAT peptide
could be predicted from the mechanism of action, as the
inhibition of the MLC-1/actin interaction may rise selec-
tively myosin motor activity and therefore muscle contrac-
tion at a given activating free Ca
2+ concentration, i.e., an
inotropic effect without additional recruitment of Ca
2+.I t
should be noted that the VLC-1-TAT peptide left the
intracellular Ca
2+-handling system unchanged, as seen by
the fact that the kinetic parameters of the Fura-2 fluores-
cence signals remained normal (Fig. 4c).
In summary, we demonstrate by live-cell microscopy
that CPPs and CPPs fused to peptides were taken up by
adult cardiomyocytes with high efficiency and localize to
their targets inside the cytoplasm and/or nucleus. The cell-
permeable peptide VLC-1-TAT accumulated in the actin-
containing I-band of the sarcomeres and was able to
enhance the contractility of isolated adult cardiomyocytes
without changing the myoplasmic Ca
2+ levels. Importantly,
the fact that VLC-1-TAT did not affect intracellular Ca
2+
concentration and that it only has targets in striated muscle
cells makes this peptide uniquely suited as a novel potential
therapeutic tool to modulate heart function. VLC-1-TAT is a
powerful new drug candidate to improve the contractile
state of the failing heart.
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